NASDAQ:ARLZ - Aralez Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started Previous Close$0.0345Today's Range$0.0345 - $0.034552-Week Range$0.02 - $2.98VolumeN/AAverage Volume5.13 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products in the areas of cardiovascular, pain management, dermatological allergy, and other indications. It offers Zontivity for the reduction of thrombotic cardiovascular events in patients with heart attack or peripheral arterial disease; Toprol-XL, a cardioselective beta-blocker that is indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia and patients with primary hypercholesterolemia or mixed dyslipidemia; and Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticarial. The company also markets Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Soriatane for the treatment of severe psoriasis and other disorders of keratinization; Proferrin, an iron supplement; Fiorinal and Fiorinal C for the relief of tension type headaches; and Bezalip SR, a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia, as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome. In addition, it provides out-licensed products, which include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and Treximet, a migraine medicine. The company was incorporated in 2015 and is headquartered in Mississauga, Canada. Receive ARLZ News and Ratings via Email Sign-up to receive the latest news and ratings for ARLZ and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:ARLZ Previous Symbol CUSIP73941U10 Webwww.aralez.com Phone905-876-1118 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees164 Outstanding SharesN/AMarket Cap$0.00 OptionableOptionable Aralez Pharmaceuticals (NASDAQ:ARLZ) Frequently Asked Questions What is Aralez Pharmaceuticals' stock symbol? Aralez Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARLZ." How were Aralez Pharmaceuticals' earnings last quarter? Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) issued its earnings results on Thursday, November, 9th. The company reported ($0.37) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.39) by $0.02. The firm had revenue of $24.30 million for the quarter, compared to analyst estimates of $22.87 million. Aralez Pharmaceuticals's quarterly revenue was up 78.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.32) earnings per share. View Aralez Pharmaceuticals' Earnings History. What price target have analysts set for ARLZ? 3 analysts have issued 12-month target prices for Aralez Pharmaceuticals' shares. Their forecasts range from $6.00 to $6.00. On average, they anticipate Aralez Pharmaceuticals' stock price to reach $6.00 in the next twelve months. View Analyst Price Targets for Aralez Pharmaceuticals. What is the consensus analysts' recommendation for Aralez Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aralez Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aralez Pharmaceuticals. Has Aralez Pharmaceuticals been receiving favorable news coverage? Press coverage about ARLZ stock has trended somewhat positive this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aralez Pharmaceuticals earned a news sentiment score of 1.1 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. Who are some of Aralez Pharmaceuticals' key competitors? Some companies that are related to Aralez Pharmaceuticals include Advanced Accelerator Application (AAAP), Aerpio Pharmaceuticals (ARPO), AgeX Therapeutics (AGE), Anthera Pharmaceuticals (ANTH), Argos Therapeutics (ARGS), ARMO Biosciences (ARMO), Biostar Pharmaceuticals (BSPM), Bohai Pharmaceuticals Group (BOPH), Cardiome Pharma (CRME), Concordia International (CXRXD), Concordia International (CXRX), Depomed (DEPO), Egalet (EGLT), Eleven Biotherapeutics (EBIO) and Immune Pharmaceuticals (IMNP). Who are Aralez Pharmaceuticals' key executives? Aralez Pharmaceuticals' management team includes the folowing people: Mr. Adrian Adams, CEO & Director (Age 67)Mr. Andrew I. Koven, Pres & Chief Bus. Officer (Age 60)Mr. Michael Kaseta, Chief Financial Officer (Age 42)Dr. James Patrick Tursi, Chief Medical Officer (Age 53)Mr. John E. Barnhardt CPA, Principal Accounting Officer and VP of Fin. & Admin. (Age 68) How do I buy shares of Aralez Pharmaceuticals? Shares of ARLZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Aralez Pharmaceuticals' official website? The official website for Aralez Pharmaceuticals is http://www.aralez.com. How can I contact Aralez Pharmaceuticals? Aralez Pharmaceuticals' mailing address is 7100 WEST CREDIT AVENUE SUITE 101, MISSISSAUGA A6, L5N 0E4. The company can be reached via phone at 905-876-1118 or via email at [email protected] MarketBeat Community Rating for Aralez Pharmaceuticals (NASDAQ ARLZ)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 223 (Vote Outperform)Underperform Votes: 219 (Vote Underperform)Total Votes: 442MarketBeat's community ratings are surveys of what our community members think about Aralez Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARLZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARLZ will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/14/2018 by MarketBeat.com StaffFeatured Article: Should you buy a closed-end mutual fund?